An NK1R antagonist dose-dependently suppressed inflammatory cytokines triggered by Substance P in human intervertebral disc cells, identifying a potential drug target for disc-related back pain.
Dose-dependent cytokine suppressionNK1R antagonist shut down IL-1β, IL-6, and IL-8 production in disc cells at increasing doses, confirming Substance P receptor blockade as a viable anti-inflammatory strategy
What the researchers found
The NK1R antagonist (L-760735) suppressed Substance P-induced expression of IL-1β, IL-6, and IL-8 in human disc cells in a dose-dependent manner, confirming that NK1R is responsible for Substance P's pro-inflammatory effects in disc tissue.
Substance P stimulation increased phosphorylation of p38-MAPK and ERK1/2 but did not activate NF-κB p65 — a surprising finding since NF-κB is often the assumed inflammatory pathway. Specific inhibitors of p38 (SB203580) and ERK1/2 (PD98059) reduced SP-induced IL-6 production, confirming these pathways as the relevant signaling cascades. All three neurokinin receptors (NK1R, NK2R, NK3R) were detected in both annulus fibrosus and nucleus pulposus disc cells.
Why it matters
Chronic back pain from disc degeneration affects hundreds of millions of people worldwide, and current treatments (painkillers, steroids, surgery) are often inadequate. This study identifies a specific molecular target — the NK1 receptor — that could be blocked to reduce inflammation directly in disc tissue. Unlike broad anti-inflammatory drugs, targeting Substance P signaling could address the root cause of disc inflammation without widespread side effects.
How the study worked
In vitro laboratory study using human intervertebral disc cells (both annulus fibrosus and nucleus pulposus). Cells were expanded in monolayer culture, then suspended in alginate beads to maintain a 3D environment. Cells were treated with the NK1R antagonist L-760735 at different concentrations, then stimulated with Substance P. Gene expression of inflammatory cytokines (IL-1β, IL-6, IL-8) was measured by quantitative RT-PCR. Signaling pathway activation was assessed by Western blot for phosphorylated p38-MAPK, ERK1/2, and NF-κB p65. Specific pathway inhibitors confirmed the signaling mechanisms.
What this study cannot tell us
This is an in vitro study using cultured human disc cells in alginate beads, which doesn't fully replicate the complex environment of a living disc. The study tested only one NK1R antagonist (L-760735). Cell culture conditions may alter receptor expression and signaling compared to in vivo. The clinical translation — whether blocking NK1R in disc tissue would reduce pain in patients — remains untested. The source and condition of the human disc cells (healthy vs. degenerated) could affect results.
How to read the evidence
This is a preclinical in vitro study using human disc cells in culture. While it provides clear mechanistic evidence, it is far from demonstrating clinical efficacy. No animal models or human trials are included.
When this study was published
Published in 2015 in Spine, a leading orthopedic journal. The study established foundational knowledge about Substance P signaling in disc cells. Research on NK1R antagonists for disc degeneration has continued since.
The bigger picture
Substance P has long been known as a pain peptide, but its role in driving inflammation within spinal disc tissue has only recently been explored. This study fills a critical gap by mapping the exact signaling pathways in human disc cells and showing they can be pharmacologically blocked. NK1R antagonists already exist as drugs (some were developed for nausea and depression) — this research suggests they could potentially be repurposed or reformulated for treating discogenic back pain, a condition affecting a significant portion of the global population.
Questions still open
- Could NK1R antagonists delivered directly to spinal discs reduce chronic back pain in clinical trials?
- Why does Substance P use p38-MAPK and ERK1/2 pathways rather than NF-κB in disc cells, and does this differ from other tissues?
- Would combining NK1R blockade with existing disc therapies produce synergistic anti-inflammatory effects?
Common questions
What is Substance P and why does it matter for back pain?
Are NK1R antagonist drugs already available?
Read the original research
Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
Spine, 40(16), 1261-9
Citation
Kepler, Christopher K; Markova, Dessislava Z; Koerner, John D; Mendelis, Joseph; Chen, Chiu-Ming; Vaccaro, Alexander R; Risbud, Makarand V; Albert, Todd J; Anderson, D Greg. (2015). Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.. Spine, 40(16), 1261-9. https://doi.org/10.1097/BRS.0000000000000954